Comparison of 5-FU versus FUDR activity in human colorectal cancer using an in vitro clonogenic assay (HTCA).

Abstract:

:Comparative in vitro drug testing was performed in 72 of 183 surgically removed human colorectal cancer specimens (34 primary lesions, 38 metastases). In 10 of these tumors, comparative dose-response curves were obtained. Given a greater than or equal to 70% ICF (inhibition of colony formation) as threshold for in vitro sensitivity, 5-FU was active in 16/62 specimens, and FUDR in 14/62. Significantly discordant sensitivity results were observed in 8/62 tests, 5-FU being the more active agent in 5 of these cases. These data are supported by the finding of 3 considerably differing dose-response curves in 10 additional comparative studies of human primary tumors.

authors

Flentje M,Flentje D,Schlag P

doi

10.1007/BF00273390

subject

Has Abstract

pub_date

1986-01-01 00:00:00

pages

223-5

issue

3

eissn

0344-5704

issn

1432-0843

journal_volume

18

pub_type

杂志文章
  • Stability of the i.v. and oral formulations of etoposide in solution.

    abstract::Etoposide is a widely used cytotoxic drug that requires complex formulation for both the i.v. and oral preparation to ensure drug stability. Data on the stability of the i.v. formulation when diluted in infusion fluids are contradictory, and there is little information on the stability of the oral preparation in gastr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685638

    authors: Joel SP,Clark PI,Slevin ML

    更新日期:1995-01-01 00:00:00

  • Reduced dose pegfilgrastim is associated with less bone pain without increased neutropenia: a retrospective study.

    abstract:BACKGROUND:Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE:Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS:Record...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3607-7

    authors: Lower EE,Charif M,Bartelt M

    更新日期:2018-07-01 00:00:00

  • Cystatin C as a predictor factor in patients with renal cell carcinoma treated by everolimus.

    abstract:BACKGROUND:We evaluated the influence of serum cystatin C (CysC) with respect to other glomerular filtration rate (GFR) markers on the treatment effect of everolimus in a phase II study in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS:Outcomes were from the study's primary analysis. GFR w...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-016-3084-9

    authors: Bodnar L,Stec R,Dzierżanowska M,Synowiec A,Cierniak S,Kade G,Szczylik C

    更新日期:2016-08-01 00:00:00

  • Autophagy, a novel target for chemotherapeutic intervention of thyroid cancer.

    abstract:PURPOSE:Thyroid cancers with unsatisfactory curative effect nowadays are the most common malignant tumors of the endocrine system. Apoptosis evasion, a hallmark of cancer, has driven the search of stimulating novel cell death way in cancer therapy. This review aims to explore the relationship between autophagy and thyr...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,评审

    doi:10.1007/s00280-013-2363-y

    authors: Li LC,Liu GD,Zhang XJ,Li YB

    更新日期:2014-03-01 00:00:00

  • Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice.

    abstract::In an attempt to establish a relationship between the pharmacokinetics in mouse heart of new anthracycline derivatives and their potential chronic cardiotoxicity and on this way to provide a useful and economical test for screening of new analogs, we followed the accumulation and metabolism of six anthracyclines in th...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00255483

    authors: Deprez-de Campeneere D,Baurain R,Trouet A

    更新日期:1982-01-01 00:00:00

  • Effects of DFMO-induced polyamine depletion on human tumor cell sensitivity to antineoplastic DNA-crosslinking drugs.

    abstract::We investigated the effect of pretreatment with difluoromethylornithine (DFMO), an ornithine decarboxylase inhibitor, on the cytocidal responses of four human adenocarcinoma cell lines to two alkylating and crosslinking agents: chlorambucil and N,N',N"-triethylenethiophosphoramide (thiotepa). The cell lines studied in...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00299860

    authors: Seidenfeld J,Komar KA,Naujokas MF,Block AL

    更新日期:1986-01-01 00:00:00

  • Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study.

    abstract:PURPOSE:The aim of the present study was to develop a new strategy for combined thermo-chemotherapy of cancer. For this purpose, we used ultrasound waves [1 MHz; 1 W/cm2; 10 min] in combination with a sonosensitizing nanoplatform, named ACA, made of alginate co-loaded with cisplatin and gold nanoparticles (AuNPs). MET...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-019-03961-9

    authors: Irajirad R,Ahmadi A,Najafabad BK,Abed Z,Sheervalilou R,Khoei S,Shiran MB,Ghaznavi H,Shakeri-Zadeh A

    更新日期:2019-12-01 00:00:00

  • Effect of cyclosporine on colchicine partitioning in the rat liver.

    abstract::Colchicine is secreted into bile as a major pathway of elimination. Cyclosporine (CsA) inhibits colchicine biliary secretion. In the present study, the effects of cyclosporine and its vehicle (cremophor) on the partitioning of colchicine across the liver were studied. CsA decreased the colchicine bile/plasma ratio fro...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685886

    authors: Speeg KV,Maldonado AL

    更新日期:1993-01-01 00:00:00

  • Morphonuclear characterization of drug resistance by means of digital cell-image analysis: an in vitro assessment.

    abstract::The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to asse...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00685647

    authors: Pauwels O,Kiss R

    更新日期:1995-01-01 00:00:00

  • High-dose dexamethasone for prevention of cis-platin-induced vomiting.

    abstract::Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00258206

    authors: Aapro MS,Alberts DS

    更新日期:1981-01-01 00:00:00

  • Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells.

    abstract:PURPOSE:The histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances cisplatin [cis-diammine dichloroplatinum (II)] (CDDP)-induced apoptosis in the oral squamous cell carcinoma (OSCC) cell line by complex, multifunctional mechanisms. We investigated the role of endoplasmic reticulum (ER) stress i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-009-0969-x

    authors: Suzuki M,Endo M,Shinohara F,Echigo S,Rikiishi H

    更新日期:2009-11-01 00:00:00

  • A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.

    abstract:PURPOSE:Based on our mouse xenograft model demonstrating that intermittent high-dose gefitinib sensitizes tumors to subsequent treatment with taxanes, we initiated this phase I trial to explore docetaxel in combination with escalating doses of intermittent gefitinib (Iressa) given prior to docetaxel. METHODS:This was ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0286-6

    authors: Fury MG,Solit DB,Su YB,Rosen N,Sirotnak FM,Smith RP,Azzoli CG,Gomez JE,Miller VA,Kris MG,Pizzo BA,Henry R,Pfister DG,Rizvi NA

    更新日期:2007-03-01 00:00:00

  • Efficacy and safety of liposome-paclitaxel and carboplatin based concurrent chemoradiotherapy for locally advanced lung squamous cell carcinoma.

    abstract:OBJECTIVE:The aim of this study was to evaluate the efficacy and toxicities of liposome-paclitaxel and carboplatin concurrent with radiotherapy for locally advanced lung squamous cell carcinoma (LSCC). METHODS:The clinical data of 38 patients with locally advanced LSCC treated with liposome-paclitaxel based concurrent...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-018-3640-6

    authors: Chen G,Sheng L,Du X

    更新日期:2018-09-01 00:00:00

  • Phase I trial of combination therapy of cancer with N-phosphonacetyl-L-aspartic acid and dipyridamole.

    abstract::While N-phosphonacetyl-L-aspartic acid (PALA), an inhibitor of de novo pyrimidine biosynthesis, demonstrated a unique spectrum of activity during preclinical drug evaluation, multiple clinical trials have shown it to possess minimal clinical activity. One explanation for the disappointing results is the possibility th...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00296262

    authors: Markman M,Chan TC,Cleary S,Howell SB

    更新日期:1987-01-01 00:00:00

  • Pharmacokinetic analysis and antitumor efficacy of MKT-077, a novel antitumor agent.

    abstract::MKT-077 (1-ethyl-2-[[3-ethyl-5-(3-methylbenzothiazolin-2-yliden)]-4- oxothiazolidin-2-ylidenemethyl] pyridinium chloride), a novel rhodacyanine dye in phase I/II clinical trials, may provide a new approach to cancer therapy based on the accumulation in the mitochondria of the cells of certain carcinomas, for example, ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050898

    authors: Tatsuta N,Suzuki N,Mochizuki T,Koya K,Kawakami M,Shishido T,Motoji N,Kuroiwa H,Shigematsu A,Chen LB

    更新日期:1999-01-01 00:00:00

  • Role of protein kinase C in adriamycin-induced erythroid differentiation of K562 cells.

    abstract::Modulators of protein kinase C (PKC) were used to investigate the role of this enzyme during Adriamycin-induced erythroid differentiation of K562 cells. Adriamycin (0.1 microM) induced erythroid differentiation in 60% +/- 10% of K562 cells. Phorbol myristate-12-acetate, an activator of protein kinase C, was strongly a...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00689696

    authors: Hoffman R,Newlands ES

    更新日期:1991-01-01 00:00:00

  • Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract.

    abstract::The present study deals with the influence of some bis(eta 5-cyclopentadienyl)titanium(IV) (titanocene) complexes, mainly represented by titanocene dichloride, on the development of several human gastrointestinal (GI) carcinomas (one stomach, seven colon, four sigmoid, and two rectal adenocarcinomas), all xenografted ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00451646

    authors: Köpf-Maier P

    更新日期:1989-01-01 00:00:00

  • Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.

    abstract:BACKGROUND:Camptothecin (CPT) is an anticancer agent that kills cells by converting DNA topoisomerase I into a DNA-damaging agent. Although CPT and its derivatives are now being used to treat tumors in a variety of clinical protocols, the low water solubility of the drug and its unique pharmacodynamics and reactivity i...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-002-0463-1

    authors: Minko T,Paranjpe PV,Qiu B,Lalloo A,Won R,Stein S,Sinko PJ

    更新日期:2002-08-01 00:00:00

  • Preclinical pharmacology of the antitumor agent O-6-methylguanine in CDF1 mice.

    abstract::O-6-methylguanine (O6-mG), a guanine analog recently shown to be a potent inhibitor of alkylguanine-DNA alkyltransferase, has been found to potentiate the antitumor activity of nitrosoureas, in particular, carmustine (BCNU), in resistant cell lines (HT-29 mer+) and is targeted for development as a modulating agent wit...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00686216

    authors: Avramis VI,Chan KK,Solorzano MM,Chen ZL

    更新日期:1993-01-01 00:00:00

  • Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.

    abstract:PURPOSE:The purpose of this investigation was to evaluate the effectiveness of oral 5-(phenylthio)acyclouridine (PTAU) in reducing 5-fluorouracil (FUra) host-toxicity and enhancing its chemotherapeutic efficacy against human colon tumors. PTAU is a potent and specific inhibitor of uridine phosphorylase (UrdPase, EC 2.4...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0213-x

    authors: Al Safarjalani ON,Rais R,Shi J,Schinazi RF,Naguib FN,el Kouni MH

    更新日期:2006-11-01 00:00:00

  • Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.

    abstract:PURPOSE:Platinum-based chemotherapy is the recognized first-line treatment for metastatic nasopharyngeal carcinoma (NPC). However, no standard treatment regimens have been established. This phase II study was designed to evaluate the efficacy and safety of a paclitaxel, cisplatin and 5-FU combination in metastatic and/...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-2020-x

    authors: Chen C,Wang FH,An X,Luo HY,Wang ZQ,Liang Y,Zhang L,Li YH

    更新日期:2013-02-01 00:00:00

  • Absence of cross-resistance between two alkylating agents: BCNU vs bifunctional galactitol.

    abstract::Dianhydrogalactitol (DAG) increased the life span of both BCNU-sensitive and -resistant L1210 tumor-bearing mice. However, the BCNU-resistant strain showed slightly lower sensitivity against DAG, which could be overcome by an increase in drug dose of ca. 20%. The somewhat lower sensitivity was proportional to a slight...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00304764

    authors: Institóris E,Szikla K,Otvös L,Gál F

    更新日期:1989-01-01 00:00:00

  • The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.

    abstract:PURPOSE:Low-dose methotrexate (MTX) therapy is the cornerstone treatment of acute lymphoblastic leukemia (ALL) and may enhance the activation of 6-mercaptopurine (6-MP) to 6-thioguanine nucleotides (6-TGN). Yet, data have established that high-dose MTX (HDMTX) hampers the accumulation of 6-TGN in red blood cells (RBC) ...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-009-1205-4

    authors: Adam de Beaumais T,Dervieux T,Fakhoury M,Medard Y,Azougagh S,Zhang D,Yakouben K,Jacqz-Aigrain E

    更新日期:2010-09-01 00:00:00

  • Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.

    abstract:PURPOSE:The safety and tolerability of vandetanib (ZACTIMA; ZD6474) plus FOLFIRI was investigated in patients with advanced colorectal cancer (CRC). METHODS:Patients eligible for first- or second-line chemotherapy received once-daily oral doses of vandetanib (100 or 300 mg) plus 14-day treatment cycles of FOLFIRI. RE...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00280-008-0914-4

    authors: Saunders MP,Wilson R,Peeters M,Smith R,Godwood A,Oliver S,Van Cutsem E

    更新日期:2009-09-01 00:00:00

  • Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours.

    abstract:PURPOSE:To evaluate the antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a vascular disrupting agent currently under phase II clinical trials in combination with cancer chemotherapy, in rats bearing chemically induced primary mammary tumours. METHODS:Tumours were induced in female Wistar rats by in...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-006-0321-7

    authors: Liu JJ,Ching LM,Goldthorpe M,Sutherland R,Baguley BC,Kirker JA,McKeage MJ

    更新日期:2007-04-01 00:00:00

  • Formation, intracellular distribution and efflux of glutathione-bimane conjugates in drug-sensitive and -resistant MCF-7 cells.

    abstract::The rate of reaction of monochlorobimane with glutathione (GSH) was measured in native human mammary MCF-7 adenocarcinoma cells (MCF-7wt) and sublines displaying resistance to 4-hydroperoxycyclophosphamide (MCF-7hc) and adriamycin (MCF-7adr) prior to examination by epifluorescence and confocal microscopy. After a 60-m...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050633

    authors: Millis KK,Lesko SA,Gamcsik MP

    更新日期:1997-01-01 00:00:00

  • Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin.

    abstract::Long-term results were analyzed in terms of tumor progression and survival in patients with superficial bladder cancer who were enrolled in the second intravesical chemoprophylactic study of the Japanese Urological Cancer Research Group for Adriamycin, which was started in July 1982. This study was a prospective, rand...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00686935

    authors: Akaza H,Koiso K,Kotake T,Matsumura Y,Isaka S,Machida T,Obata K,Ohashi Y,Ohe H,Ohi Y

    更新日期:1992-01-01 00:00:00

  • In vitro comparative studies of the myelotoxicity and antitumor activity of 6-[bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose versus melphalan utilizing the CFU-C and HTSCA assays.

    abstract::6-[Bis-(2-chloroethyl)-amino]-6-deoxy-D-glucose (C-6) is a new glucose-containing nitrogen mustard that has significant activity for murine P388 leukemia with relative sparing of bone marrow in mice. The in vitro myelotoxicity of C-6 compared with that of melphalan, a clinically active, myelosuppressive nitrogen musta...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/BF00256165

    authors: Lazarus P,Dufour M,Isabel G,Panasci LC

    更新日期:1986-01-01 00:00:00

  • Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions.

    abstract:PURPOSE:Patupilone (EPO906) is a novel potent microtubule stabilizer, which has been evaluated for cancer treatment. A novel physiologically based pharmacokinetics (PBPK) model was developed based on nonclinical data to predict the disposition of patupilone in cancer patients. METHODS:After a single intravenous dose (...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s00280-012-1863-5

    authors: Xia B,Heimbach T,Lin TH,He H,Wang Y,Tan E

    更新日期:2012-06-01 00:00:00

  • Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.

    abstract::Recent studies in human bone-marrow culture and healthy human volunteers suggest that lenograstim [glycosylated, recombinant human granulocyte colony-stimulating factor (rHuG-CSF) produced in Chinese hamster ovary (CHO) cells] has greater in vivo potency than filgrastim [nonglycosylated, methionine-extended recombinan...

    journal_title:Cancer chemotherapy and pharmacology

    pub_type: 杂志文章

    doi:10.1007/s002800050570

    authors: Nohynek GJ,Plard JP,Wells MY,Zerial A,Roquet F

    更新日期:1997-01-01 00:00:00